Cisplatin is a type of broad-spectrum anti-carcinogen that has been widely used in anti-gastric cancer therapy. Drug resistance prevails in gastric cancer therapy. α-Hederin has been reported to exert anti-tumour ability by inducing apoptosis in many cancers in vitro and in vivo. A combination chemotherapy regimen can improve the outcome of patients. In the present study, we used a CCK-8 assay, Hoechst 33258 staining, Annexin V-PE/7-AAD, intracellular reactive oxygen species (ROS) measurement, mitochondrial membrane potential (MMP) assay kit and western blotting to detect apoptosis and mitochondrial function in gastric cancer (GC) cells. A xenograft tumour model in nude mice was used to evaluate the anti-tumour effects of cisplatin and α-Hederin in vivo. Combination treatment of cisplatin and α-Hederin increased the apoptotic effects in cisplatin-induced GC cell lines. In the xenograft mouse model, the combination of cisplatin and α-Hederin remarkably increased the tumour inhibition effect compared to either drug alone. Interestingly, combination of cisplatin and α-Hederin increased the expression of apoptosis-related proteins. Using in vitro experiments, we verified that the combination of cisplatin and α-Hederin increased the accumulation of ROS in GC cell lines and also reduced the MMP, thus inhibiting proliferation and promoting apoptosis in GC cells. α-Hederin enhances cisplatin-induced anti-tumour effects in GC both in vitro and in vivo by promoting the accumulation of ROS and decreasing MMP. Our data strongly suggested that α-Hederin is a promising candidate for intervention in gastric cancer.
Sarcopenia and ulcerative colitis (UC) may share potential biological links through mechanisms involving immune dysregulation, gut microbiota imbalance, and inflammatory pathway activation. This study aimed to identify fatty acid metabolism-related shared genes between UC and sarcopenia. A total of 277 shared differentially expressed genes (sDEGs) were identified, which were mainly enriched in immune-, inflammation-, and metabolism-related pathways. By intersecting the sDEGs with fatty acid metabolism-related gene sets, 13 fatty acid metabolism-related shared differentially expressed genes (FAM-sDEGs) were obtained, and unsupervised clustering based on these genes stratified UC patients into distinct molecular subtypes. Using machine learning and feature-ranking methods, PHYH and HSD17B3 were ultimately identified as key hub genes. ROC analysis showed that these two genes exhibited diagnostic value for both sarcopenia and UC across multiple datasets. In addition, the expression of the hub genes was significantly associated with immune cell infiltration profiles and was further validated in independent datasets. Preliminary validation in a UC cell model confirmed the downregulation of PHYH, while immunohistochemical analysis of colonic tissues further supported the downregulated expression of PHYH in patients with UC, consistent with the bioinformatics results. Collectively, these findings suggest that fatty acid metabolism may play an important role in the shared molecular features between UC and sarcopenia, and that PHYH may serve as potential diagnostic biomarkers.